We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).Alk+ France […]
Follow Us
-
+1 700 888 1234
-
Effingerstrasse 40 3008 Bern Switzerland
+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).Alk+ France […]
Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]
We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]
We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last […]
Lung Cancer Europe (LuCE) Annual General Meeting and General Assembly The Lung Cancer Europe (LuCE) AGM and General Assembly take […]
Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]
consectetur adipisicing elit, sed do eiusmod tempor incididunt laboret dolore magna aliqua. Ut enim minim veniam quis nostrud exercitation ullamco laboris.
